Yang Liu, Wang Wei, Fan Yanbo, Lin Zheren, Zhang Yisheng, Zeng Qingfeng
Department of Pharmacy, Wuhan Hospital of Traditional Chinese Medicine, Wuhan, Hubei 430050, China.
Evid Based Complement Alternat Med. 2022 Dec 21;2022:6709506. doi: 10.1155/2022/6709506. eCollection 2022.
Diabetes seriously threatens the health of people. Traditional Chinese medicine has been proven to inhibit the progression of diabetes. Meanwhile, the Xiaotangzhike pill (XTZK) was known to alleviate the symptom of diabetes. Thus, this research decided to investigate the mechanism underlying the impact of XTZK in diabetes remains unexplored.
To assess the impact of XTZK in diabetes, in vivo model of diabetes was constructed. The contents of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C) in the rats were tested by the commercial kits. In addition, Masson and hematoxylin and eosin (H&E) staining were applied for assessing the histological changes and fibrosis in the rats, respectively. Furthermore, a western blot was applied to assess the protein levels.
Streptozotocin (STZ) significantly increased the levels of area under the curve (AUC), TG, TC, LDL-C, and decreased the contents of HDL-C in rats, while these phenomena were partially reversed by XTZK. In addition, STZ notably induced inflammatory infiltration and fibrosis in the liver tissues of rats, which was greatly restored by XTZK. The levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and malondialdehyde (MDA) in the serum of rats were notably upregulated by STZ, while the effect of STZ was markedly abolished by XTZK. Meanwhile, STZ-caused the upregulation of p-Smad2 and -SMA in rats was restored by XTZK. Furthermore, XTZK notably inhibited the progression of Qi and Yin deficiency syndrome in diabetes through the mediation of the Akt/GSK-3 axis.
The Xiaotangzhike pill attenuates the progression of diabetes through the mediation of the Akt/GSK-3 axis. Hence, our study might supply a novel insight into discovering new strategies against diabetes.
糖尿病严重威胁人们的健康。中医已被证明可抑制糖尿病的进展。同时,已知消糖止渴丸(XTZK)可缓解糖尿病症状。然而,XTZK对糖尿病影响的潜在机制仍未得到探索。
为评估XTZK对糖尿病的影响,构建了糖尿病体内模型。使用商用试剂盒检测大鼠体内总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)和高密度脂蛋白胆固醇(HDL-C)的含量。此外,分别应用Masson染色和苏木精-伊红(H&E)染色评估大鼠的组织学变化和纤维化情况。此外,采用蛋白质印迹法评估蛋白质水平。
链脲佐菌素(STZ)显著增加大鼠曲线下面积(AUC)、TG、TC、LDL-C水平,并降低HDL-C含量,而XTZK可部分逆转这些现象。此外,STZ显著诱导大鼠肝组织炎症浸润和纤维化,XTZK可使其得到显著恢复。STZ显著上调大鼠血清中天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)和丙二醛(MDA)水平,而XTZK可显著消除STZ的这种作用。同时,XTZK可恢复STZ导致的大鼠p-Smad2和α-平滑肌肌动蛋白(α-SMA)上调。此外,XTZK通过介导Akt/糖原合成酶激酶-3(GSK-3)轴显著抑制糖尿病气阴两虚证的进展。
消糖止渴丸通过介导Akt/GSK-3轴减轻糖尿病的进展。因此,我们的研究可能为发现抗糖尿病新策略提供新的见解。